Middle East and Africa Cervical Cancer Diagnostic Testing Market Developments by 2028

The MEA cervical cancer diagnostic testing market is expected to grow from US$ 218.90 million in 2021 to US$ 282.38 million by 2028; it is estimated to grow at a CAGR of 3.7% from 2021 to 2028.

The cervical cancer diagnosis test market players focus on launching new products to expand their geographic reach and enhance capacities to cater to a greater than existing customer base. In November 2021, Hologic, Inc. launched the Genius Digital Diagnostics System for cervical cancer screening. Next-generation screening systems combine deep earning-based artificial intelligence (AI) with the latest volumetric imaging technology to assess precancerous lesions and cervical cancer cells in women. Similarly, in 2019, BD’s COR PX/GX system was launched, which is available in centralized labs across region since 2019 to assist in high-volume processing and increase overall efficiency. Similarly, one popular government insurance program provides cover for PAP tests, pelvic exams, and clinical breast examinations performed every two years for cervical cancer screening. Such programs and developments and launches of new products are likely to bring new trends in the MEA cervical cancer diagnosis test market in the coming years, thereby supporting its growth.In case of COVID-19, MEA is highly affected especially South Africa. The healthcare sector in the UAE has undergone a considerable number of infrastructure and procedural changes to position itself as a leading healthcare provider. These improvements have been more recently recognized throughout the COVID-19 pandemic due to the continuous investments made to improve the sector’s hard and soft infrastructure. However, COVID-19 is likely to continue to have a notable impact on healthcare operations in countries. The pandemic had a major impact on a wide range of health outcomes. Disordering of elective health services related to cervical screening, management of abnormal screening test results, and treatment of pre-cancers, that lead to increase in cervical cancer incidence and inflame existing health disproportions. Since, the beginning of 2020, the pandemic has caused enormous health, social and economic impacts, likely to continue in 2021. Even after some of these impacts have been mitigated or contained, there will be medium and longer-term consequences. In many countries, diagnostics services have been disrupted, and supply chains for key commodities have been stretched. In Africa, COVID-19 has threatened the control of major health conditions including cervical cancer. As COVID-19 continues to spread in Africa, there are concerns over its impact on market, limited diagnosis, and decreased access to expert gynecologists further impacting the market in the region. However, as the pandemic situation overcomes, the demand for several diagnostics modalities used in cervical cancer diagnosis will increase. 
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA cervical cancer diagnostic testing market. The MEA cervical cancer diagnostic testing market is expected to grow at a good CAGR during the forecast period. 

MEA Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)     

 

MEA Cervical Cancer Diagnostic Testing Market Segmentation 

MEA Cervical Cancer Diagnostic Testing Market – By Type

• PAP Testing
• HPV Testing
• Colposcopy
• Cervical Biopsies
• Cystoscopy
• Others

MEA Cervical Cancer Diagnostic Testing Market – By Service Provider

• Diagnostics and Research Laboratories
• Hospitals and Clinics
• Specialty Clinics
• Home Care Services

MEA Cervical Cancer Diagnostic Testing Market, by Country

• South Africa
• Saudi Arabia   
• UAE 
• Rest of MEA

MEA Cervical Cancer Diagnostic Testing Market - Companies Mentioned

• Abbott
• BD
• Cooper Companies, Inc.
• F. Hoffmann-La Roche Ltd.  
• Femasys Inc.
• Guided Therapeutics, Inc
• Hologic, Inc.  
• QIAGEN
• Quest Diagnostics Incorporated   

Middle East and Africa Cervical Cancer Diagnostic Testing Report Scope